$147.76
Value $365B
Merck & CompanyvsBio-Techne
MRK and TECH stock compared: price, dividend, valuation and results, from SEC filings.
+0.55%
$72.80
Value $11.4B
Merck & Company (MRK) has a market value of $365B and Bio-Techne (TECH) $11.4B. Over the last year, with dividends, MRK moved +66.3% and TECH +19.4%. The P/E is 148.9 for MRK and 66.5 for TECH. Dividend yield: MRK 2.30%, TECH 0.44%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MRK$365B
TECH$11.4B
MRK is 32 times TECH
Revenue, 12 months
MRK$67.4B
TECH$1.2B
MRK is 55 times TECH
Net income, 12 months
MRK$2.5B
TECH$172M
MRK is 14 times TECH
Operating margin
MRK–
TECH19.6%
ROIC
MRK3.9%
TECH7.7%
3.8 points apart
P/E
MRK148.9
TECH66.5
MRK is 2.2 times TECH
Dividend yield
MRK2.3%
TECH0.4%
1.9 points apart
5-year return
MRK+104.9%
TECH-40.9%
145.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MRK+104.9%
TECH-40.9%
| Period | MRKWith dividends | TECHWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +66.3%Price +61.6% | +19.4%Price +18.6% |
| 3 years since November 13, 2023 | +58.0%+16.5% a yearPrice +44.2% | +29.5%+9.0% a yearPrice +27.5% |
| 5 years since November 12, 2021 | +104.9%+15.4% a yearPrice +75.9% | -40.9%-10.0% a yearPrice -42.3% |
| 10 years since November 15, 2016 | +230.1%+12.7% a yearPrice +143.3% | +190.5%+11.3% a yearPrice +174.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
MRKMerck & CompanyTECHBio-Techne
Valuation
MRKTECH| Price | $147.76 | $72.80 |
|---|---|---|
| Market value | $365B | $11.4B |
| Enterprise value (EV) | $409B | $11.5B |
| P/E | 148.9 | 66.5 |
| P/E, 5-year median | 14.8 | 56.6 |
| P/B | 8.1 | 5.3 |
| EV/EBIT | 86.0 | 47.7 |
| Free cash flow yield | 4.0% | 2.7% |
Results and growth
MRKTECH| Revenue, 12 months | $67.4B | $1.2B |
|---|---|---|
| Net income, 12 months | $2.5B | $172M |
| Free cash flow, 12 months | $14.7B | $308M |
| Earnings per share, 12 months | $0.98 | $1.09 |
| Revenue growth, year on year | 1.3% | -0.4% |
| Revenue growth a year, past | +9.4%over 5 years | +5.5%over 5 years |
| EPS growth a year, past | +21.2%over 5 years | +5.9%over 5 years |
Margins and returns on capital
MRKTECH| Gross margin | 71.8% | 65.8% |
|---|---|---|
| Operating margin | – | 19.6% |
| Net margin | 3.6% | 14.0% |
| ROIC | 3.9% | 7.7% |
| ROE | 5.2% | 8.3% |
Balance sheet
MRKTECH| Cash | $9.7B | $350M |
|---|---|---|
| Total debt | $53.8B | $486M |
| Net debt / EBITDA | 5.7 | 0.2 |
| Interest cover | 2.4× | 27.2× |
Dividends and buybacks
MRKTECH| Dividend yield | 2.3% | 0.4% |
|---|---|---|
| Dividend per share, 12 months | $3.40 | $0.32 |
| Dividend growth a year, past | +5.8%over 5 years | +0.0%over 5 years |
| Buyback yield | 1.4% | 0.4% |
| Shareholder yield | 3.7% | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Merck & Company or Bio-Techne?
By market value, Merck & Company ($365B) is about 32.0 times Bio-Techne ($11.4B), at today's prices.
How did MRK and TECH stock do over the last 10 years?
Since November 15, 2016, MRK's price moved +143.3% and TECH's +174.4%. With dividends: MRK +230.1% (+12.7% a year), TECH +190.5% (+11.3% a year). Past returns do not predict future ones.
Which pays the higher dividend, MRK or TECH?
The dividend yield at today's price is 2.30% for Merck & Company and 0.44% for Bio-Techne. Over the last twelve months they paid $3.40 and $0.32 per share.
What is the P/E of MRK and TECH?
At today's price, the P/E is 148.9 for MRK and 66.5 for TECH. The median of the last five years was 14.8 and 56.6, which shows where each stands against its own past.
Which has the higher profit margins, Merck & Company or Bio-Techne?
Over the last twelve months, the net margin was 3.6% for Merck & Company and 14.0% for Bio-Techne, and the operating margin – and 19.6%. Revenue was $67.4B and $1.2B.
Which is the better investment, Merck & Company or Bio-Techne?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.